


# TINOX (BAS vs. BMS)

Prospective, Multi-center, Randomized Trial:

Titanium-Nitride-Oxide Coated Stents  
vs. Bare Metal Stents



## 5-YEAR FOLLOW-UP

### TRIAL DESIGN

- 92 patients enrolled
- Randomization 1:1
- Endpoints: LATE LOSS at 6 months and MACE at 5 years

### CLINICAL CHARACTERISTICS

	TINOX* BAS	CONTROL* BMS	p-value
Previous myocardial infarction, n (%)	19 (42)	18 (38)	0.80
Smoking	16 (36)	21 (45)	0.40
Diabetics	15 (34)	16 (34)	0.99
History of CAD	17 (39)	15 (32)	0.66
Hypertension	33 (73)	34 (72)	0.99
Hypercholesterolemia	38 (84)	32 (68)	0.05


### LESION CHARACTERISTICS

	TINOX* BAS	CONTROL* BMS	p-value
A lesions (%)	9	31	0.03
B1/B2 lesions (%)	84	63	ns
C lesions (%)	7	6	ns
RVD (mm)	2.85 ± 0.39	2.91 ± 0.40	ns
Lesion length (mm)	9.9 ± 3.5	10 ± 4.5	ns

\* TINOX: Titanium-Nitride-Oxide coated stents (BAS: Bio Active Stent)  
CONTROL: uncoated Stainless steel stents (BMS: Bare Metal Stent)


# TINOX (BAS vs. BMS) Prospective, Multi-center, Randomized Trial: Titanium-Nitride-Oxide Coated Stents vs. Bare Metal Stents

## 6-MONTH RESULTS



Titanium-Nitride-Oxide coated stents reduce significantly Late Loss by 40% vs. BMS at 6 months.


## 5-YEAR RESULTS



**Circulation**  
JOURNAL OF THE AMERICAN HEART ASSOCIATION  
Circulation - 2005 ; 111:2617-2622

The Efficacy and Safety of Titanium-Nitride-Oxide coated stents are significantly superior at 5 years.

## FOLLOW-UP AVAILABLE UP TO 5 YEARS



The long term clinical benefits of Titanium-Nitride-Oxide coated stents are **sustained** up to 5 years.

Non contractual document - REV00-12/2008

### HEXACATH

4, Passage Saint-Antoine - 92508 Rueil-Malmaison Cedex  
Tel: +33 (0)1 41 39 01 92 - Fax: +33 (0)1 41 39 01 93  
Web: www.hexacath.com

**TCT 2008**  
TRANSCATHETER CARDIOVASCULAR THERAPEUTICS

Speaker: O. Hess